Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Strategic Integration of Imatinib (STI571) in Patient-Der...
2025-10-01
This thought-leadership article explores how selective protein-tyrosine kinase inhibitors, specifically Imatinib (STI571), are revolutionizing translational research by enabling mechanistic dissection of tumor–stroma interactions within advanced assembloid models. We synthesize recent evidence from patient-derived gastric cancer assembloids, provide actionable experimental guidance, and chart a course for integrating Imatinib into next-generation personalized cancer research.
-
Decoding Tumor Complexity: Strategic Integration of Imati...
2025-09-30
Harnessing Imatinib (STI571) for precise manipulation of tyrosine kinase signaling pathways, this thought-leadership article guides translational researchers in leveraging next-generation assembloid models to overcome tumor microenvironment challenges and accelerate personalized cancer therapies. By fusing mechanistic insights, competitive analysis, and actionable experimental design, we chart a roadmap for integrating selective kinase inhibition into the vanguard of cancer biology research.
-
Imatinib (STI571): Unraveling Tyrosine Kinase Pathways in...
2025-09-29
Explore the pivotal role of Imatinib (STI571), a selective protein-tyrosine kinase inhibitor, in dissecting tyrosine kinase signaling pathways and overcoming tumor microenvironment challenges in personalized cancer biology research. Discover unique insights into resistance mechanisms and translational applications, grounded in the latest assembloid model advances.
-
Imatinib (STI571): Targeted Kinase Inhibition for Advance...
2025-09-28
Explore the advanced applications of Imatinib (STI571), a selective protein-tyrosine kinase inhibitor, in cancer biology research. This article provides an in-depth analysis of its mechanism, specificity, and unique role in translational models for tumor microenvironment studies.
-
Influenza Hemagglutinin (HA) Peptide: Precision Tool for ...
2025-09-27
Discover the unique advantages of the Influenza Hemagglutinin (HA) Peptide as a molecular biology peptide tag in dissecting ubiquitin signaling and E3 ligase function. This in-depth analysis explores advanced HA tag peptide applications for protein-protein interaction research and cancer biology.
-
HyperScribe™ Poly (A) Tailing Kit: Driving mRNA Therapeut...
2025-09-26
Explore how the HyperScribe™ Poly (A) Tailing Kit advances polyadenylation of RNA transcripts for next-generation mRNA therapeutics. This in-depth analysis uniquely focuses on translational and in vivo applications, highlighting technical nuances and recent breakthroughs in mRNA delivery.
-
PD 0332991 (Palbociclib) HCl: Decoding CDK4/6 Inhibition ...
2025-09-25
Explore the molecular intricacies of PD 0332991 (Palbociclib) HCl as a selective CDK4/6 inhibitor, emphasizing its role in cell cycle G1 phase arrest and novel apoptotic pathways. Uncover unique mechanistic insights grounded in recent RNA Pol II research, advancing breast cancer and multiple myeloma studies.
-
AZD0156: A Paradigm Shift in Targeting ATM Kinase for Syn...
2025-09-24
Explore how AZD0156, a potent ATM kinase inhibitor, enables the rational design of synthetic lethality strategies in cancer therapy research. This in-depth analysis uniquely examines metabolic vulnerabilities, combination tactics, and translational insights beyond DNA damage response.
-
Triptolide as a Molecular Tool: Insights into Genome Acti...
2025-09-23
Explore the multifaceted roles of Triptolide, a potent IL-2/MMP-3/MMP7/MMP19 inhibitor, in dissecting genome activation mechanisms and disease-relevant signaling in cancer and immunology research. This article provides a rigorous analysis of Triptolide's molecular actions, its application in developmental biology, and its emerging utility beyond conventional anti-inflammatory and anticancer studies.
-
The mechanism of transformation into SCLC is unclear but
2025-03-03

The mechanism of transformation into SCLC is unclear but the loss of retinoblastoma gene (RB) seems important and constitutes an initial event in the tumorigenic process. Some reports revealed the role of the RB gene loss in EGFR mutated NSCLC who transformed into SCLC [15]. In NGS we retrieved mut
-
Curcumin is able to upregulate the protein
2025-03-03

Curcumin is able to upregulate the protein level of NGF through cannabinoid receptor CB1, where the activation of Akt pathway probably plays an important part in the CB1-mediated signal transmission [9,10]. This finding suggested that the protection of curcumin in spinal motor neurons of SNI rats is
-
br Conclusion The HT receptor
2025-03-03

Conclusion The 5-HT receptor family is complex, and one may ask as does Bryan Roth et al. [205] whether this is useless punicalagin (i.e. too much redundancy) or an embarrassment of the riches (i.e. many potential targets to choose from to affect normal or pathological function); molecular biolo
-
neohesperidin dihydrochalcone Pioneering studies on the immu
2025-03-03

Pioneering studies on the immunomodulatory role of adenosine date back to the early ‘70 s of last century (Fig. 1), when the critical role of this nucleoside in shaping the development and the activity of several immune cell populations was first established [[18], [19], [20], [21], [22]]. This then
-
In the late s Solvay Pharmaceuticals discontinued the Phase
2025-03-03

In the late ‘90s, Solvay Pharmaceuticals discontinued the Phase 2 development of a promising potent and highly selective A1AR antagonist based on the pyrrolopyrimidine scaffold, SLV320 [43] (2, Chart 1, also named derenofylline; Ki hA1AR = 1 nM), for the treatment of acute heart failure [24]. In the
-
Until now the molecular interactions
2025-03-03

Until now, the molecular interactions of Tmod or Lmod with 66 8 had been assessed in pyrene-actin polymerization assays [13], [23], [27], [28], [44], [45] or directly measured using non-denaturing polyacrylamide gel-electrophoresis (for Tmod isoforms only [23]), ITC (for Tmod1 and Lmod2) [43], [46]
14985 records 11/999 page Previous Next First page 上5页 1112131415 下5页 Last page